Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine Infusion for OCD
NCT01349231Phase 2Completed
- Sponsor
- Yale University
- Start
- Feb 2009
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine in obsessive compulsive disorder (OCD), sponsored by Yale University. Primary endpoint: OCD Severity at 3 days. Started Feb 2009; status: completed.
02
Drugs
ketamine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT01349231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01349231.